Video: St. Jude Children's Research Hospital Spotlights Successes and Challenges...

Video: St. Jude Children's Research Hospital Spotlights Successes and
Challenges of Childhood Cancer
St. Jude Honors National Childhood Cancer Awareness Month

MEMPHIS, Tenn. Sept. 16 /PRNewswire/ -- Advances in diagnosis and treatment
mean more children are living longer with cancer than ever before, with about
270,000 childhood cancer survivors alive today nationwide. Despite these
advances, cancer remains the leading cause of death due to disease among U.S.
children over one year of age.

To View the Multimedia News Release, go to:
http://www.prnewswire.com/mnr/stjude/40088/

September is National Childhood Cancer Awareness Month, but for researchers at
St. Jude Children's Research Hospital it is a year round mission to research
new ways to help more children live long, active lives while also working to
better understand the challenges childhood cancer survivors face.

"Our goal is to push the cure rate for all childhood cancers to 90 percent in
the next decade. Rapid advances in science and technology, especially at the
genetic level, are going to make that possible," said Dr. William E. Evans,
St. Jude director and chief executive officer. St. Jude is the nation's only
cancer center focused solely on childhood cancer.

This year cancer will be diagnosed in more than 10,000 children and
adolescents age 14 and younger. For some, including those with acute
lymphoblastic leukemia (ALL), the fear of diagnosis will be tempered by the
optimism of cure rates near 90 percent thanks to researchers at St. Jude and
other institutions around the world. For other children diagnosed with cancer,
optimism is in shorter supply. Despite decades of research, cure rates for
some childhood cancers remain below 50 percent.

St. Jude investigators recently reported in the New England Journal of
Medicine that they had reached the critical 10-year cure rate of 90 percent
for patients with ALL, a cancer of the white blood cells. This year ALL will
be diagnosed in about 3,000 U.S. children, making it the most common childhood
cancer. More tailored chemotherapy linked to the genetics of the patient and
the patient's tumor combined with more sophisticated monitoring of the
patient's response to treatment, have been key to the improved survival.

Researchers believe the next generation of tools to understand, diagnose and
treat cancer will come from the study of cancer cells and mapping the human
cancer genome or blueprint. Technological advances have enhanced the speed and
reduced the cost of decoding the genes in a patient's cancer cells and
comparing them to the DNA in normal cells. St. Jude is at the forefront of
pediatric cancer genome research, with a goal to catalogue the genetic changes
that give rise to the uncontrolled cell division that is a hallmark of all
cancers.

In order to better understand cancer cells, researchers need access to tissue
samples. The researchers at St. Jude are uniquely positioned to conduct this
type of research because the hospital is home to one of the world's largest
and most complete repositories of biological information about childhood
cancer. Collected since the 1970s, St. Jude has more than 50,000 biological
samples from patients who agree to participate. The bank's contents include
tumor, bone marrow, plasma, serum and blood samples.

As the most common solid malignancies of childhood, brain tumors are a leading
cause of cancer death in children. Improved survival rates in certain brain
tumors like medulloblastoma, where patient cure rates are nearing 75 percent,
are being helped by research at St. Jude. But similar rates have been
difficult to achieve for other brain tumors, including gliomas and some germ
cell tumors. By linking studies of neurodevelopment and clinical
investigations of brain tumors, researchers are working to translate
laboratory findings into potential new treatments.

The pediatric Neurobiology and Brain Tumor Program at St. Jude is one of the
nation's largest. The program's recent efforts include the integration of
genome-wide gene expression and genetic microarray profiling to improve brain
tumor classification and treatment.

"We at St. Jude are never satisfied with where we are," Evans said. "When we
come to work we're trying to push cure rates higher and higher."

For more information about childhood cancer, go to www.stjude.org.

St. Jude Children's Research Hospital
St. Jude Children's Research Hospital is internationally recognized for its
pioneering work in finding cures and saving children with cancer and other
catastrophic diseases. Founded by late entertainer Danny Thomas and based in
Memphis, Tenn., St. Jude freely shares its discoveries with scientific and
medical communities around the world. No family ever pays for treatments not
covered by insurance, and families without insurance are never asked to pay.
St. Jude is financially supported by ALSAC, its fundraising organization.

SOURCE St. Jude Children's Research Hospital

Summer Freeman, +1-901-595-3061, Summer.Freeman@stjude.org, Carrie Strehlau,
+1-901-595-2295, Carrie.Strehlau@stjude.org